The Keller Laboratory at cc-TDI

Thursday, July 30, 2009

Congratulations to Corrine, a TST Scholar !

Many congratulations to Corrine on being selected by the Institute for Integration of Medicine and Science as Translational Science Training (TST) Program Scholar for 2009/2010! This competitive CTSA program, and Corrine was selected as one of 6 recipients by a 16-member interdisciplinary committee. The award encompasses a stipend, travel to a national meeting and funds for research. We are all so proud of Corrine's accomplishment!

Friday, July 24, 2009

Sarcoma Awareness Fun Run/ Walk & Social a Success !

Many heartfelt thanks to Melinda Garcia and Corrine Chua for the wonderful planning that made for today's very successful "Team Sarcoma San Antonio" event. We met at Pavilion 3 in McAllister Park where we had a fun run/walk followed by a cook-out and social. “Sarcoma Knows No Borders” bracelets benefiting the Liddy Shriver Sarcoma Initiative went quickly. We were especially pleased that this year's event was well shaded and nearby a great playground for the children of participants.

For other recent Sarcoma Awareness events across Texas, click here.

To send your comments about this year's event and suggestions for next year's, feel free to email Melinda at GarciaM20@uthscsa.edu

pictured: Team Sarcoma San Antonio (TeSSA) 2009 event!

Thursday, July 23, 2009

Drug Development Conference

The Cancer Molecular Therapeutics Research Association (CMTRA) annual meeting was held at Stanford University from July 19 -22. This is an interesting intersection of academics and the pharmaceutical industry whereby confidential data presentations allow free and open intellectual exchanges about the science and implementation of drug development and clinical trials. For those interested in molecular therapeutics, this meeting is a true gem. From our lab, Jinu's work on IGF receptor inhibition was very well received.

[ pictured top right: an artwork on the Stanford campus by Auguste Rodin, entitled The Gates of Hell. After all, it was a cancer meeting. ]

Wednesday, July 15, 2009

Our lab featured as UTHSCSA 'Research Stars'

We are grateful for the acknowledgement of our lab's mission in the Summer 2009 UTHSCSA publication entitled, "The reSearch is On: Research-Discover-Cure" emphasizing the importance of the bench to bedside research paradigm. Vice President for Research, Dr. Brian Herman, was a critical reason we endeavored to start our research enterprise at the newly formed Greehey Children's Cancer Research Institute, and with his support we are able to move closer to fulfilling our mission every day.

Tuesday, July 7, 2009

Congratulations to Navaline!

Many congratulations to our collaborators Navaline Quach and her mentor, Tom Rando, at Stanford on their publication, "Focal Adhesion Kinase Signaling Regulates the Expression of Caveolin 3 and beta1 Integrin, Genes Essential for Normal Myoblast Fusion" in Molecular Biology of the Cell. Our lab appreciates the opportunity to have contributed to this study, which dissects the role of focal adhesion kinase in myoblast fusion and differentiation.

Wednesday, July 1, 2009

Pediatric Drug Development website Officially Launched!

The Pediatric Preclinical Testing Initiative at the Greehey Children's Cancer Research Institute has officially launched its new website, www.GivingBackChildhood.org . We're excited about this program, which uses genetically-engineered mice to validate novel molecularly-targeted therapies for use in children with cancer.

We sincerely thank our early and current sponsors, including a kind anonymous donor, the Joanna MacAfee Foundation and the Rally Foundation.

Monday, June 22, 2009

Welcoming Steven

Summer intern Steven McCarthy is a welcome new addition the our pediatric cancer research team. Steven is an undergraduate at Florida State University (Tallahassee) where he's majoring in Biomedical Engineering with minors in physics and biology. Steven is also captain for the FSU Men's Water Polo team and recently joined the Biomedical Engineering Society, a prestigious distinction in his field of study.

Cross-disciplinary contributors like Steven make new approaches possible. Welcome, Steven!

You Can Participate in our Novel Therapeutics Studies !

One would like to think that tangibly better treatments for rhabdomyosarcoma, medulloblastoma and other childhood cancers can be found in a matter of years, instead of tens of years. Finding new treatments starts with research, perhaps even a new research approach to identifying effective new treatments. The Children's Cancer Therapy Development Institute focuses on finding molecules in childhood cancers that can be directly turned off or on by drugs so that the tumor stops growing. Behind our novel approach is the use of genetically-engineered mice. Our Pediatric Preclinical Testing Initiative uses mice modified from before birth so that at a certain age, and in a certain tissue, the same mutations found in a child’s cancer are activated in the mouse. These special mouse models of childhood cancer can be used to test a treatment to see whether the tumor growth and spread (metastasis) can be reversed. The specific aspect of these mice having normal immune systems is a real plus, too, because white blood cells play an important role in how tumors evolve and respond to therapy.

Our program is designed around community participation. Through the Children's Cancer Therapy Development Institute, you can contribute directly to this grass-roots initiative. Donations through small gifts or grants will assist in studying compounds that may be effective in treating such childhood cancers as alveolar rhabdomyosarcoma, embryonal rhabdomyosarcoma, or medulloblastoma (the alveolar rhabdomyosarcoma model was featured by Dr. Keller's long time collaborator and former mentor, 2007 Nobel laureate Mario Capecchi, in his Nobel Prize lecture {see 16 minutes onward}.)

For additional information regarding supporting this program please contact Charles Keller at charles@cc-tdi.org. Results obtained through these studies will be shared with the National Cancer Institute’s Cancer Therapy Evaluation Program, as well as the Children’s Oncology Group, which designs clinical trials for childhood cancer.